New PMP Criteria
新薬創出加算の新要件

The price maintenance premium (PMP) (新薬創出加算; shinyaku soshutsu kasan ) , which has been in place since its pilot rollout in April 2010, has been hailed by the research-oriented pharmaceutical industry as the centerpiece of Japan’s pro-innovation policy. While it...

To read the full story

LEXICON

G1/G2 RuleG1/G2ルール
March 9, 2018
Cost Calculation Method原価計算方式
July 27, 2017
Sakigake Designation Scheme先駆け審査指定制度
August 17, 2016
Special expansion re-pricing (Huge-seller re-pricing)特例拡大再算定（巨額再算定）
March 4, 2016
Market expansion re-pricing市場拡大再算定
March 4, 2016

Takeda’s £46 Billion Shire Buyout

Shareholders Give Blessing to £46 Billion Shire Pact as Weber Touts US Foothold

Takeda Pharmaceutical CEO Christophe Weber highlighted the importance of gaining a strong foothold in the world’s largest pharma market at…

TRENDS

Generic Industry at Crossroads: Companies Face Pressing Need to Boost Profitability ahead of FY2020

By Reiji Anasako

While generic drugs post solid growth in volume-based shares in Japan, their makers are pondering ways to retool their business…

COMMENTARY

Does Dissolution of Japan Vaccine Signal Demise of Model in Vaccine Industry Vision, or Will a Second Round of JV Take Place?

By Yoshinori Sagehashi

Daiichi Sankyo and GlaxoSmithKline recently announced that they have agreed to dissolve their joint venture company, Japan Vaccine. The failure of this model of joint venture between a major Japanese and foreign drug maker in just six years is disappointing.Over…

COLUMN

Expat Truths from the Japanese Medical Device World

By Gregory Ng